Merck's most recent trend suggests a bearish bias. One trading opportunity on Merck is a Bear Call Spread using a strike $85.00 short call and a strike $90.00 long call offers a potential 19.33% return on risk over the next 6 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $85.00 by expiration. The full premium credit of $0.81 would be kept by the premium seller. The risk of $4.19 would be incurred if the stock rose above the $90.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Merck is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Merck is bearish.
The RSI indicator is at 43.66 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Merck
Cross-Sector: Market Data Highlights
Thu, 10 Sep 2020 15:29:06 +0000
Merck's Pneumococcal Vaccine Meets Goals in Late-Stage Studies
Thu, 10 Sep 2020 14:38:02 +0000
Merck's (MRK) investigational 15-valent pneumococcal conjugate vaccine meets primary immunogenicity objectives in two late-stage studies in adults.
Merck to Present at the Morgan Stanley 18th Annual Virtual Global Healthcare Conference
Thu, 10 Sep 2020 10:45:00 +0000
Merck to Present at the Morgan Stanley 18th Annual Virtual Global Healthcare Conference
Johnson & Johnson stock rises Wednesday, still underperforms market
Wed, 09 Sep 2020 20:25:00 +0000
COMPANY CLOSE UPDATES Terrence Horan Shares of Johnson & Johnson JNJ rose 1.66% to $149.70 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 2.
Merck Announces Detailed Data on Late-Stage Cough Candidate
Wed, 09 Sep 2020 15:14:03 +0000
Merck (MRK) announced detailed data from two pivotal studies evaluating gefapixant in patients with refractory or unexplained chronic cough.
Related Posts
Also on Market Tamer…
Follow Us on Facebook